Sedative Hypnotic Class Labeling Warns Of Sleep-Driving And “Complex” Behaviors
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA requests manufacturers of 13 sleep aids, including Ambien, Lunesta and Rozerem, to update labeling to advise of adverse events.
You may also be interested in...
Somaxon’s Silenor Could Launch In Early ’09 Pending Partnering Discussions
Somaxon submits an NDA for the insomnia medication, setting it up for potential FDA approval in December, firm tells "The Pink Sheet" DAILY.
Somaxon’s Silenor Could Launch In Early ’09 Pending Partnering Discussions
Somaxon submits an NDA for the insomnia medication, setting it up for potential FDA approval in December, firm tells "The Pink Sheet" DAILY.
Ambien Publicity Sets The Whole Class On Snooze, Sanofi Says
Despite an initial dip in sales during Q1 stemming from a class action suit, Sanofi-Aventis says growth of the insomnia drug returned to previous levels.